Exposure-response analyses of sacituzumab govitecan (SG) efficacy and safety in patients (pts) with metastatic triple-negative breast cancer (mTNBC).

被引：0
|
作者：
Singh, Indrajeet
Sathe, Abhishek G.
Singh, Pratap
Diderichsen, Paul M.
Fauchet, Floris
Maringwa, John
Pierrillas, Philippe
Phan, See-Chun
Girish, Sandhya
Othman, Ahmed A.
机构：
[1] Gilead Sci Inc, Foster City, CA USA
[2] Certara USA Inc, Princeton, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1076
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Exposure-Response Analyses of Sacituzumab Govitecan Efficacy and Safety in Patients With Metastatic Triple-Negative Breast Cancer
    Sathe, Abhishek G.
    Diderichsen, Paul M.
    Fauchet, Floris
    Phan, See-Chun
    Girish, Sandhya
    Othman, Ahmed A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2025, 117 (02) : 570 - 578
  • [2] Exposure-response analyses of sacituzumab govitecan efficacy and safety in patients with metastatic breast cancer
    Singh, Indrajeet
    Sathe, Abhishek
    Diderichsen, Paul
    Witjes, Han
    Van Schanke, Arne
    Maringwa, John
    Verret, Wendy
    Girish, Sandhya
    Othman, Ahmed
    CANCER RESEARCH, 2024, 84 (09)
  • [3] Pharmacokinetics (PK) of sacituzumab govitecan (SG) in patients (Pts) with metastatic triple-negative breast cancer (mTNBC) and other solid tumors
    Sathe, A. G.
    Singh, I.
    Singh, P.
    Diderichsen, P.
    Wang, X.
    Chang, P.
    Phan, S-C.
    Girish, S.
    Othman, A. A.
    ANNALS OF ONCOLOGY, 2022, 33 : S214 - S214
  • [4] Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Updated phase 2 safety and efficacy results
    Seneviratne, Lasika C.
    Harnden, Kathleen Kiernan
    Blau, Sibel
    Danso, Michael A.
    Berz, David
    Guaqueta, Delia Constanza
    Schwerkoske, John F.
    O'Shaughnessy, Joyce
    Patt, Debra A.
    Bardia, Aditya
    McCann, Kelly Elizabeth
    Beelen, Andrew Paul
    Zhang, Jingshan
    Yi, John S.
    Hurvitz, Sara A.
    Mardones, Mabel Alejandra
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Assessment of sacituzumab govitecan (SG) in Black patients (pts) from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC)
    Carey, Lisa A.
    Zelnak, Amelia
    Rugo, Hope S.
    Dalenc, Florence
    Nanda, Rita
    Danso, Michael
    Saghatchian, Mahasti
    Kalinsky, Kevin
    Firmin, Nelly
    Ruiz-Borrego, Manuel
    Favret, Anne
    Sun, Jun
    Schwartzberg, Lee
    Hilton, Christie
    Omene, Coral
    Young, Robyn
    Hurvitz, Sara A.
    Harting, Eliza
    Phan, See
    Bardia, Aditya
    CANCER RESEARCH, 2022, 82 (04)
  • [6] Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)
    Hegewisch-Becker, S.
    Oliveira, M.
    Traina, T.
    Tolaney, S. M.
    Loirat, D.
    Punie, K.
    Hurvitz, S. A.
    Lynce, F.
    Hamilton, E.
    Nanda, R.
    Hart, L.
    Richards, P.
    Malik, Z.
    Rugo, H. S.
    Dieras, V
    Bardia, A.
    Hong, Q.
    Phan, S.
    Itri, L. M.
    Loibl, S.
    Kalinsky, K.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 242 - 242
  • [7] Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC).
    Kalinsky, Kevin
    Oliveira, Mafalda
    Traina, Tiffany A.
    Tolaney, Sara M.
    Loirat, Delphine
    Punie, Kevin
    Hurvitz, Sara A.
    Lynce, Filipa
    Hamilton, Erika P.
    Nanda, Rita
    Hart, Lowell L.
    Richards, Paul D.
    Malik, Zulfiqar A.
    Rugo, Hope S.
    Dieras, Veronique
    Bardia, Aditya
    Hong, Quan
    Olivo, Martin Sebastian
    Itri, Loretta
    Loibl, Sibylle
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Assessment of sacituzumab govitecan (SG) in patients (pts) with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC)
    Hegewisch-Becker, S.
    Loirat, D. L.
    Punie, K.
    Bardia, A.
    Dieras, V
    Dalenc, F.
    Diamond, J. R.
    Fontaine, C.
    Wang, G.
    Rugo, H. S.
    Hurvitz, S. A.
    Kalinsky, K.
    O'Shaughnessy, J.
    Carey, L. A.
    Loibl, S.
    Gianni, L.
    Piccart, M.
    Hong, Q.
    Phan, S.
    Itri, L. M.
    Cortes, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 133 - 133
  • [9] Metastatic triple-negative Breast Cancer (mTNBC) First-in-class Therapy with Sacituzumab Govitecan
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (1-2) : 64 - 65
  • [10] Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
    Bardia, A.
    Hurvitz, S. A.
    Tolaney, S. M.
    Loirat, D.
    Punie, K.
    Oliveira, M.
    Brufsky, A.
    Sardesai, S. D.
    Kalinsky, K.
    Zelnak, A. B.
    Weaver, R.
    Traina, T.
    Dalenc, F.
    Aftimos, P.
    Lynce, F.
    Diab, S.
    Cortes, J.
    O'Shaughnessy, J.
    Dieras, V
    Ferrario, C.
    Schmid, P.
    Carey, L. A.
    Gianni, L.
    Piccart, M. J.
    Loibl, S.
    Goldenberg, D. M.
    Hong, Q.
    Olivo, M. S.
    Itri, L. M.
    Rugo, H. S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16): : 1529 - 1541
12345